Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

PharmaCyte Biotech, Inc. (PMCB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.1800+0.0900 (+4.31%)
At close: 04:00PM EDT
2.1700 -0.01 (-0.46%)
After hours: 04:17PM EDT
Advertisement

PharmaCyte Biotech, Inc.

23046 Avenida de la Carlota
Suite 600
Laguna Hills, CA 92653
United States
917 595 2850
https://www.pharmacyte.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Mr. Kenneth L. Waggoner Esq.Chairman, CEO, Pres, Gen. Counsel & Sec.433.33kN/A1948
Mr. Carlos A. Trujillo CPA, CPACFO & Director300kN/A1958
Dr. Gerald W. Crabtree Ph.D.Chief Scientific Officer & Director94.33kN/A1941
Dr. Jose L. Iglesias M.D.Consulting Chief Medical OfficerN/AN/A1957
Dr. Hans-Peter HammesMember of Medical & Scientific Advisory Board and ConsultantN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cells. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is based in Laguna Hills, California.

Corporate Governance

PharmaCyte Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement